Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,911.97 +3,511.25 (+5.81%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
IOVA Jan 2025 25.000 call
| Previous close | 1.8500 |
| Open | 1.5500 |
| Bid | 0.7500 |
| Ask | 1.8000 |
| Strike | 25.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.5500 - 1.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 897 |
GlobeNewswireIovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or
- GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences: Chardan Annual Genetic Medicines & Cell Therapy Manufacturing Summit Fireside Chat: April 30, 2024 at 2:30 p.m. ETVirtual The Citizens JMP Life Scienc
Simply Wall St.With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners
Key Insights Given the large stake in the stock by institutions, Iovance Biotherapeutics' stock price might be...
